newsfilter
← Latest News
GlobeNewswire·

Adagio Therapeutics Reports First Quarter 2022 Financial Results

$532.2 Million in Total Cash at Quarter End; Strong Balance Sheet Expected to Support Operations into Second Half of 2024 Additional Data from Adintrevimab Phase 2/3 STAMP Treatment Trial to be Presented at ASM Annual Meeting WALTHAM, Mass., May 1